Last reviewed · How we verify
Juvista (Avotermin)
Avotermin is a recombinant human transforming growth factor beta-3 (TGF-β3) that modulates wound healing to reduce scarring.
Avotermin is a recombinant human transforming growth factor beta-3 (TGF-β3) that modulates wound healing to reduce scarring. Used for Reduction of scar formation in acute surgical wounds, Improvement of cosmetic outcomes in wound healing.
At a glance
| Generic name | Juvista (Avotermin) |
|---|---|
| Also known as | juvista, RN1001, Juvista, RN1001, TGFβ3 |
| Sponsor | Renovo |
| Drug class | Recombinant growth factor |
| Target | TGF-β3 (Transforming Growth Factor Beta-3) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Wound Healing |
| Phase | Phase 3 |
Mechanism of action
Avotermin works by enhancing the inflammatory phase of wound healing and promoting a fetal-like healing response that minimizes collagen deposition and scar formation. By exogenously delivering TGF-β3 at the wound site, it shifts the healing process toward regeneration rather than fibrosis, resulting in improved cosmetic outcomes and reduced scar visibility.
Approved indications
- Reduction of scar formation in acute surgical wounds
- Improvement of cosmetic outcomes in wound healing
Common side effects
- Erythema at injection site
- Edema
- Pruritus
- Local irritation
Key clinical trials
- Juvista in Scar Revision Surgery of Disfiguring Scars (PHASE3)
- A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (PHASE1)
- Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids (PHASE1, PHASE2)
- Juvista (Avotermin) in Scars Following Varicose Vein Removal (PHASE2)
- Safety of Juvista When Administered Following Excision of Ear Lobe Keloids (PHASE1, PHASE2)
- Juvista in the Non-surgical Improvement of Existing Scars (NA)
- Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects (PHASE1, PHASE2)
- Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Juvista (Avotermin) CI brief — competitive landscape report
- Juvista (Avotermin) updates RSS · CI watch RSS
- Renovo portfolio CI